Name: Cynata Therapeutics (CYP) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

CYP

Pharmaceuticals, Biotechnology & Life Sciences

Cynata Therapeutics

Short interest: 0.00%; −0.62 pp 30d; as of 13 May 2026
Reported shorts: 3.1K
Shares on issue: 243.454M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Cynata Therapeutics

Cynata Therapeutics is a clinical-stage biotechnology company focused on developing and commercialising its proprietary Cymerus™ platform technology, which generates induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs). This innovative platform provides a scalable and consistent source of MSCs, positioning Cynata as a potential leader in 'off-the-shelf' regenerative medicine with applications across various inflammatory, autoimmune, and degenerative diseases.

Company profile →

Cynata Therapeutics (ASX:CYP) has 0.00% of its shares on issue reported as short positions as of 13 May 2026, or about 3,127 shares. Over the past 30 days that figure has fallen 0.62 percentage points, and over 90 days it has fallen 0.62 percentage points. Its highest recorded short interest was 0.63% in November 2024. CYP is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads CYP today

Zanger BreakoutWatchScore 18rank 1351 of 1942
CAN SLIMNot a candidate
Minervini Trend TemplateNot a candidate
Crowded-Short BreakoutWatchScore 18rank 417 of 1500
Quality compoundersNot a candidate

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

CYP fundamentals

In the year to 30 Jun 2026, Cynata Therapeutics (ASX:CYP) recorded revenue of A$79.5K and a net loss after tax of A$9.2M. A year earlier it recorded revenue of A$227.7K and a net loss after tax of A$9.4M. Year-on-year growth: revenue −65.1% (FY). Net margin −11,635.2% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →